Posted by Michael Wonder on 14 Dec 2021
Trastuzumab deruxtecan supplemental new drug application submitted in Japan for treatment of patients with HER2 positive metastatic breast cancer
14 December 2021 - Submission based on groundbreaking DESTINY-Breast03 phase 3 trial, in which trastuzumab deruxtecan demonstrated a 72% reduction in the risk of disease progression or death versus trastuzumab emtansine.
Daiichi Sankyo today announced that it has submitted a supplemental new drug application to Japan’s Ministry of Health, Labour and Welfare for trastuzumab deruxtecan, a HER2 directed antibody drug conjugate, for the treatment of adult patients with HER2 positive unresectable or recurrent breast cancer previously treated with trastuzumab and a taxane.
